Alpha-adrenergic blockers: mechanism of action, blood pressure control, and effects of lipoprotein metabolism (Q37608000)

21 August 2017

1 reference

title

Alpha-adrenergic blockers: mechanism of action, blood pressure control, and effects of lipoprotein metabolism (English)

1 reference

21 August 2017

1 reference

Nash DT

1

1 reference

21 August 2017

1 November 1990

1 reference

21 August 2017

1 reference

21 August 2017

13

1 reference

21 August 2017

764-772

1 reference

21 August 2017

11

1 reference

The pharmacological basis for the use of alpha 1-adrenoceptor antagonists in the treatment of essential hypertension

21 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

Acute and chronic haemodynamic effects of doxazosin in hypertension at rest and during exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

Acute renal effects of doxazosin in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

The antihypertensive effects of doxazosin: a clinical overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

Antihypertensive effect of doxazosin in hypertensive patients: comparison with atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

Double-blind comparison of the effects of long-term treatment with doxazosin or atenolol on serum lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

Mechanism of alpha blockade for blood pressure control

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

7 January 2021

New developments in alpha-adrenergic receptor pharmacology: Implications for the initial treatment of hypertension

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

7 January 2021

Role of alpha adrenoceptors in hypertension and in antihypertensive drug treatment.

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

7 January 2021

Selective alpha1-adrenergic antagonists: Therapeutically relevant antihypertensive agents

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

7 January 2021

Effectiveness of prazosin as initial antihypertensive therapy

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

7 January 2021

Initial antihypertensive drug therapy: alpha blocker or diuretic. Interim report of a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

7 January 2021

Effects of two antihypertensive agents on lipids, lipoproteins, and apoproteins A and B. Comparison of prazosin and atenolol

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

7 January 2021

A multicenter trial of doxazosin in West Germany

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

7 January 2021

An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension.

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

7 January 2021

Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

7 January 2021

Comparison of the safety and efficacy of once-daily terazosin versus twice-daily prazosin for the treatment of mild to moderate hypertension

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

7 January 2021

The effects of terazosin and methyclothiazide on blood pressure and serum lipids

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

7 January 2021

A double-blind parallel trial to assess the efficacy of doxazosin, atenolol and placebo in patients with mild to moderate systemic hypertension

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

7 January 2021

Comparison of the effects of doxazosin and atenolol on blood pressure and blood lipids: a one-year, double-blind study in 228 hypertensive patients.

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

7 January 2021

Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

7 January 2021

Serum lipid changes in a one-year, multicenter, double-blind comparison of doxazosin and atenolol for mild to moderate essential hypertension

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

7 January 2021

Multicenter, double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

7 January 2021

A 24-week multicenter double-blind study of doxazosin and hydrochlorothiazide in patients with mild to moderate essential hypertension

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

7 January 2021

Comparative effects of doxazosin and hydrochlorothiazide on serum lipids and blood pressure in essential hypertension

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

7 January 2021

Pharmacokinetic overview of doxazosin

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

7 January 2021

24-hour control of blood pressure by once daily doxazosin: a multicentre double-blind comparison with placebo

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

7 January 2021

Antihypertensive therapy and lipids. Paradoxical influences on cardiovascular disease risk

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

7 January 2021

Adrenergic effects on plasma lipoprotein metabolism. Speculation on mechanisms of action

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

7 January 2021

Adrenergic mechanisms in the control of plasma lipids in man

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

7 January 2021

Effects of alpha-adrenergic and beta-adrenergic receptor blockade on lipid metabolism.

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

7 January 2021

Alpha-1-adrenergic blockade and lipoprotein metabolism in essential hypertension

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

7 January 2021

Reduction of plasma triglyceride concentration by acute stress in man

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

7 January 2021

Disparate effects of prazosin and propranolol on lipid metabolism in a rat model

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

7 January 2021

Doxazosin increases low density lipoprotein receptor activity.

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

7 January 2021

Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960131104

7 January 2021

Identifiers

DOI

10.1002/CLC.4960131104

1 reference

21 August 2017

1 reference

PubMed ID

1980236